Care of HIV-infected pregnant women in maternalfetal medicine programs
Authors: Sklar P. A.1; Bathgate S. L.2; Young H. A.3; Parenti D. M.1
Source: Infectious Diseases in Obstetrics and Gynecology, Volume 9, Number 2, 1 June 2001 , pp. 81-87(7)
Publisher: Taylor and Francis Ltd
Abstract:
Objective: To survey the evolution over the past decade of attitudes and practices of obstetricians in maternalfetal medicine fellowship programs regarding the management of human immunodeficiency virus (HIV)-infected pregnant women. Methods: Directors of all 65 approved maternalfetal medicine training programs were sent questionnaires, responses to which were to reflect the consensus among members of their faculties. Programs were stratified based upon the number of HIV-infected pregnant patients cared for in the previous year. Results: Responses reflect experience with over 1000 infected pregnant women per year, nearly one-quarter with advanced disease. Combination antiretroviral therapy was prescribed by all respondents, universally in the 2nd and 3rd trimesters. A three-drug regimen (often containing a protease inhibitor) was used more often by those who treated at least 20 HIV-infected pregnant patients per year than by those programs seeing a lower number of patients (80 vs 59%). Despite the known and unknown risks of the use of antiretrovirals during pregnancy, only half of all responding programs report adverse events to the Antiretroviral Pregnancy Registry; reporting was more common among the institutions seeing a higher number of patients (61 vs 45%). Seventy-eight percent of higher volume programs enroll their patients in clinical studies, usually multicenter, versus 35% of lower volume programs. Conclusions: Care for HIV+ pregnant women has dramatically changed over the past decade. Antiretroviral therapy is now universally prescribed by physicians involved in maternal-fetal medicine training programs. Given limited experience with these agents in the setting of pregnancy, it is essential for maternalfetal medicine practitioners to actively report on adverse events and participate in clinical trials.Keywords: HIV; VERTICAL DISEASE TRANSMISSION; ANTI-HIV AGENTS
Language: English
Document Type: Research article
Affiliations: 1: Division of Infectious Diseases, Department of Medicine, The George Washington University School of Medicine and Health Sciences, Washington, DC 2: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The George Washington University School of Medicine and Health Sciences, Washington, DC 3: Department of Biostatistics, The George Washington University School of Public Health and Health Services, Washington, DC

Click here for Page Help